A refreshed global brand signals JCR’s expanded international presence and unwavering focus on rare and genetic diseases worldwide
JCR Pharmaceuticals Co., Ltd. a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide.
Health Technology Insights: BYRD Health Earns Cloud Assurance, Boosts UDI Compliance Partnership
“At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,” said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. “In September, we celebrate the 50th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.”
The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR’s commitment to bridge the gap between complex science and unmet needs of patients and families.
Health Technology Insights: Acelpa Health Established as Integrated Specialty Infusion Platform
For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR’s pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company’s ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities.
Health Technology Insights: UPMC Ireland Chooses MEDITECH Expanse for Digital Strategy
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
